# MYND™

Life Sciences

(CSE:MYND)

Corporate Presentation July 2021

www.myndsciences.com

# Disclaimer

Market and Industry Data

This presentation by MYND Life Sciences (CSE:MYND) (the “Presentation”) includes market and industry data that has been obtained from third party sources, including industry publications. MYND Life Sciences (CSE:MYND) believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information.Although the data is believed to be reliable, MYND Life Sciences (CSE:MYND) has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article

Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) the expected development of the Company’s business, projects and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for the Company’s projects; (v) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (v) renewal of the Company’s current customer, supplier and other material agreements; and (vi) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

# About Us

**MYND Life Sciences** is a drug research and development company focused on **diagnostic approaches**, **novel psychedelic drug development**, **pharmaceuticals** and **vaccines**.

**MYND** is advancing psychedelic derived medicines based on neuro anti-inflammatory processes through rigorous scientific and clinical trials to add Major Depressive Disorder (“MDD”), Sepsis, Alzheimer’s disease and other inflammatory diseases.



# Proven Leadership

MYND Life Sciences Inc. was founded by Dr. Wilfred Jefferies and Dr Lyle Oberg with the goal of improving mental health.  Dr. Jefferies is a world-renowned Neuroimmunologist with over 60 patents and 100 publications in prestigious medical journals including  Nature and The Lancet. Through Dr. Jefferies research conducted over the past 30 years, and the executive leadership of Dr. Oberg, the two intend to establish the link between depression and inflammation in the brain and ultimately develop a pharmaceutical treatment utilizing compounds found in psilocybin.

**Dr. Lyle Oberg**,  Co-Founder and CEO

A physician by profession, Dr. Oberg possesses extensive senior leadership, finance and corporate governance experience. He was first elected to the Legislative Assembly of Alberta as a Progressive Conservative in 1993. He was first appointed to the Alberta Cabinet in 1997 and served numerous posts. He launched a western Canadian initiative to address Fetal Alcohol Syndrome and implemented an interprovincial strategy to share resources and develop new and better approaches for addressing FAS. In May 1999, Dr. Oberg was appointed Minister of Learning, He began the second language initiative in Alberta schools to give students an edge in the world marketplace and initiated the development of the daily physical activity program to improve the health of Alberta students. In 2006, Lyle Oberg was named Minister of Finance. Lyle left politics in 2008 with one of the largest surpluses in Alberta history. Dr. Oberg later opened and became CEO of C2DNA, the first private DNA testing facility in Canada. Next, Dr. Oberg joined the Flowr Corporation as CEO. Additionally, Dr. Oberg was a member of the Ernst and Young Expert Panel reviewing Alberta Health Services and their $21.9 billion annual budget and was recently appointed by Order in Council to the Physician Compensation Advisory Committee. Dr. Oberg is a director of Yorkville Asset Management which was founded in 2010 has approximately $3 billion under management. He also currently sits on the board of Centric Healthcare and Flowr Corporation.

**Dr. Wilfred Jefferies,** Co-Founder and CSO

Dr. Wilfred A. Jefferies earned his Doctor of Philosophy degree from the Sir William Dunn School of Pathology at the University of Oxford, followed by post doctorates at top academic centres in Switzerland and Sweden.  He was quickly recognized as a rising star by none other than Nobel Prize laureate Dr. Michael Smith who personally recruited him to his laboratory at the University of British Columbia ('UBC') where he continues to perform research  today.  Dr. Jefferies is recognized as a leader in the emerging field of immunotherapy and his research has resulted in new and innovative ways to use components of the body's own immune system to fight cancer, viruses and even promote brain health.  He has an uncanny ability to translate complex immunological breakthroughs into real world medical treatments. Dr. Jefferies innovative strategies and outstanding inventions enabling cancer immunotherapies and vaccines have been recognized with his induction as a Fellow of the National Academy of Inventors (NAI).  Election as a Fellow of the NAI is the highest professional distinction accorded solely to eminent academic inventors. Dr. Jefferies is also a member of the UBC Departments of Microbiology & Immunology, Medical Genetics, and Zoology, as well as the Centre for Blood Research and the Djavad Mowafaghian Centre for Brain Health.

TG Therapeutics

**Sean Power,** CPA - Capital Markets Advisor

- Highly accomplished, Pharma Executive with 16+ years of experience in financial leadership, with transactions and financings exceeding $700 million
- Part of the founding team of TG Therapeutics (NASDAQ:TGTX)
- Under his leadership as CFO, TGTX has grown to a market capitalization of over $6 billion, with 40 clinical trials underway, and 5 medicines under development.

# Company Highlights

## Collaborating With Major Research Institutions

- Collaborating with world class research facilities at **University of British Columbia's** Michael Smith Laboratory
- MYND has a **collaborative research agreement** with the University of British Columbia on **MDD**
- Experienced medical research professionals pioneering research in the field of psychedelics as anti-inflammatories
- Abcellera (Nasdaq:ABCL) was most notably incubated at the Michael Smith Laboratories ($12.65B IPO, largest biotech IPO in Canadian history)



## Extensive Research Paired With A Unique License

- [1]Four **Patents** Filed:
  - A diagnostic biomarker with the potential to diagnose and monitor MDD and other diseases
  - Modulation of key pathways in the treatment of MDD utilizing Psilocybin analogs
  - Methods for regressing or delaying Alzheimer's disease and related forms of dementia
  - Modulation of the key pathways in the in the treatment of inflammatory diseases utilizing Psilocybin analogs
- Operating under the **part J exemption granted by Health Canada** to conduct R&D on **38 unique analogs of Psilocybin**
- Advanced research into **Mycogene** gene receptor modulation via Psilocybin

[1] Patent documentation can be found in Appendix A

## Developing A Platform For Success

- **Diagnostic Biomarker Development**
  - Unique **quantitative** diagnosis of depression leveraging MYND's unique IP and **SISCAPA** patented blood assay technology
  - Near term **revenue** catalyst
- **Drug Development**
  - Two novel indications have been chosen to go into development
    - **MYND-604 targeting MDD and MYND-778 targeting Sepsis**
- **Vaccine Development**
  - **Immunoprotection and vaccine development** for the prevention of diseases of the CNS
- **Clinical Trial Development**
  - 4 Clinical trials in development with the initial trials to launch in Q4 2021

# Mental Health - A Weight On Society

[3]WHO claims depression and anxiety contribute to ~$1T per year in economic costs globally

Simply put, MDD is a very heterogeneous disorder that affects how one processes events

## Significant Patient Base With Unmet Needs

- [1]264,000,000 people suffer from depression across the globe
- About 1 out of 7 individuals experience MDD during their life time but only 1 out of 3 achieve remission with current treatment
- MDD is the 2nd largest source of disability and costs the economy in the US $200 billion annually[2]

## Lack Of Innovation From Big Pharma

- Pharma has not taken an innovative approach to R&D as we have seen little innovation to selective serotonin reuptake inhibitors (SSRIs) and antidepressants in over 20 years
- MDD and TRD have a greater than 50% chance of relapse using conventional methods of treatment
- Traditional treatments have focused solely on symptom suppression and not the root cause

## The Time For Change Is Now

- Covid has accelerated the ongoing mental health crisis in the U.S. and abroad
- In a recent CDC survey 31% of respondents reported symptoms of anxiety or depression,13% reported having started or increased substance use, 26% reported stress-related symptoms, and 11% reported having serious thoughts of suicide in the past 30 days
- These numbers are double pre-pandemic levels

[1] WHO https://www.who.int/news-room/fact-sheets/detail/depression

[2](Savitz, Laureate Institute for Brain Research)

[3]WHO Depression and the workplace report

# Combatting Neuroinflammation

**Neuroinflammation** is defined as the activation of the brain's innate immune system in response to an inflammatory challenge and is characterized by a host of cellular and molecular changes within the brain

## Clinical Evidence

- Increased circulation of pro-inflammatory cytokines found in patients with Treatment Resistance Depression (“TRP”)
- Cytokines therapy in cancer patients and interferon therapy in Patients with hepatitis C can induce depressive symptoms
- Imbalance in kynurenine metabolites pathways found in blood of depressed patient
- Anti-inflammatory compounds have antidepressant effects
- PET imaging shows activated microglia in depressed subject

[1]“When inflammation is severe, becomes chronic, or occurs during critical developmental windows or on a background of neurodegeneration or chronic severe stress, prolonged activation of interoceptive pathways and consequent neurochemical changes can precipitate long-standing maladaptive neurobiological and behavioral changes that are implicated in the pathophysiology of many common psychiatric disorders.”

[1](Savitz,2019 Interoception and Inflammation in Psychiatric Disorders)

# MYND's Core Divisons

MYND Life Sciences is advancing four strategic divisions: MDD Diagnostic Biomarker Development & Test Kits, Drug Development, Clinical Trial Development and Vaccine Development all leveraging our IP as it relates to combatting neuroinflammatory processes in the body leveraging novel psychedelics compounds

# Diagnostic Biomarker Development & Test Kits

The expansion of MYND's intellectual property portfolio to more precisely diagnose and then monitor the treatment regime for patients with MDD and other diseases of inflammation is a key division of the company's overall commercialization and **near term path revenue**




**Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA)** is a patented sample preparation methods platform for diagnostics that improves the performance of mass spectrometry (MS) for measurement of pre-selected protein targets. MYND's innovation, enabled by this technology, is a specific analyzing "standard operating procedure" specific to the Human Mycogene protein it has patented.

# A Pathway to Near Term Revenue

**MYND** is developing the capability to distribute SISCAPA peptides and protein antibody biomarker detection protocols in-house in the form of biomarker detection kits

A major differentiator of the MYND/SISCAPA's biomarker detection kit is the ability to produce test results directly from a dried **blood** or other bodily fluid sample providing a simple and more cost effective product for patients

**Cancer, autoimmune diseases, neurological and central nervous system (CNS) diseases** represent the most considerable portion of the biomarker market




MYND's Human Mycogene testing kit targets markets include: **hospitals, clinics, healthcare facilities and major diagnostic centers**. Each individual testing kit costs **$200.00** per unit

**MYND's** biomarker technology is anticipated to generate revenues of $822K in 2022, $5.6M in 2023 and $17.8M in 2024.




**Revenue will be generated through:**

- Human Mycogene Testing Kits
- Partnerships with hospitals, clinic networks and healthcare facilities
- **Future** Licensing Agreements

MYND has an established relationship with **Revitalist Treatment Clinics** to run trials for biomarker business

# Clinical Trial Development

**MYND's** robust pipeline of diagnostics, novel small molecule, and biologics, is focused on improving disease outcomes and monitoring and improving the treatment experience for patients around the world. The company plans for several clinical trials to establish the efficacy of MYND's novel diagnostics and therapeutics targeting commencement in **Q4 of 2021**

MYND's clinical trial development will be managed by Dr. Iryna Saranchova, PHD, the company's **Chief Clinical Officer**. Dr. Saranchova has **over two decades of experience in immunology and clinical research** with proven holds Certificates from The Johns Hopkins University and Vanderbilt University in Design and Interpretation of Clinical Trials, as well as in Data Management for Clinical Research. With several clinical trials designed and executed, Iryna will be a key driver MYND's clinical trials moving forward.

A- a clinical trial to identify a marker for diagnosing and monitoring, both qualitatively and quantitatively, depression in response to psilocybin treatment as well as various psychedelics

B- a clinical trial to address the therapeutic impact of psilocybin and psilocybin analogs as anti-inflammatories in diminishing cytokine storm

C- a clinical trial to address the therapeutic impact of psilocybin and psilocybin analogs on depression in patients with proven Covid 19

D- a clinical trial to address the therapeutic impact of psilocybin and psilocybin analogs on sepsis

# Drug Development Pipeline

## MYND has Two Flagship Drugs in the Drug Development Pipeline with Several Other Indications Identified

## MYND-604

MYND-604 is being developed to treat MDD and bring much needed innovation to the antiquated multi-billion dollar SSRI market. MDD is a common and severe disorder that is

Significant unmet needs exist in the management of MDD, which, if addressed successfully, would be expected to reduce overall illness-associated morbidity. A high level summary of unmet needs is as follows:

- Need to identify which patients with MDD will respond to/tolerate (or not) antidepressant therapies (ie. Personalized medicine)
- Treatments that are more (or less) likely to achieve provider-and patient-desired outcomes in MDD
- Treatments capable of attenuating critical dimension/domain-based outcomes in MDD
- Treatments that can rapidly attenuate depressive symptoms

## MYND-778

MYND-778 is being developed as an oral dosage form of psilocybin for the treatment of Sepsis. Sepsis is a bi-phasic inflammatory disease characterized by an initial hyper-inflammatory phase called systemic inflammatory response syndrome (SIRS), which is followed by an

Sepsis remains an unmet medical need, and sustained attempts by intensivists have indeed yielded an incremental improvement in outcomes.

- No step change in survival rates despite introduction of novel therapies
- Precision (or personalized) medicine (“PM”) has emerged in recent years as an approach that seeks to make use of person-specific, real-time data to choose a therapeutic regimen designed specifically for the individual patient.

# Vaccine Development Program

**MYND** has licensed **Eyam Vaccine** and Immunotherapeutics next generation, self amplifying mRNA Platform designed to build low dose, high stability, vaccines and immunotherapeutics targeting universal coverage and protection for CNS diseases

**Vaccines** and immunotherapeutics utilize the body's own defense system to fight off insults such as neuro-inflammation by proactively targeting the disease processes.

Progress has been made in the research community utilizing this technology to attack CNS disorders such as MS, Alzheimer's and other diseases of the CNS.

It is anticipated that this program will be through pre-clinical trials within 18 months.

# Business Unit Development Timelines

| Dev Stage | H2 2020 | H1 2021 | H2 2021 | H1 2022 | H2 2022 | H1 2023 |
|---|---|---|---|---|---|---|
| 1. Diagnostic Biomarker<br>Anticipated CapEx: $250,000 | **Biomarker** design is completed | | 9 unique peptides have been identified | Synthesizing of candidates is completed for trials | Commence commercialization in labs | |
| 2. MYND-604 & MYND-778<br>Clinical Trial Development | Pre clinical trials are underway and are expected to be completed by Q1 2022 | | | IND application expected 2nd quarter 2022 | Phase 2 clinical trials start 3rd quarter 2022 | |

Clinical Trials Capital Expenditure for MYND-604 & MYND-778 are an estimated $7.5M per trial.

# Leadership Team

**Dr. Lyle Oberg**
Co-Founder and Chief Executive Officer

**Dr. Iryna Saranchova, PHD**
Chief Clinical Officer

**Dr. Wilfred Jefferies**
Co-Founder and Chief Science Officer

**Dr. Cheryl Pfeifer, PHD**
Senior Research Scientist

**Jordan Cleland**
Chief Operating Officer

**Dr. Chaahat SB Singh, PHD**
Senior Research Scientist

# Advisory Team

## Mark A Geyer, PhD

Mark A. Geyer is a Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. At UCSD, he is a founding member of the Consortium for Translational Research in Neuropsychopharmacology (CTRIN) and Translational Research in Psychophysiology, Exploration, and Cognition (TRIPEC) groups. In 1993, he co-founded the Heffter Research Institute, which pioneered and supported much of the scientific research that has prompted the exploration of psychedelics as potential therapeutics in humans. He has recently co-founded the Psychedelics and Health Research Initiative at UCSD, which is exploring the effi cacy of psychedelics in the treatment of pain disorders.

UC San Diego

HARVARD UNIVERSITY

## Joseph Boyd Martin, M.D., PhD

Joseph Boyd Martin, M.D., PhD. served as Dean of the Harvard Faculty of Medicine from 1997 to 2007. Born in Bassano, Alberta, Canada in 1938, Dr. Martin received his premedical and medical education at the University of Alberta, Edmonton, earning the M.D. degree in 1962. He completed a residency in neurology in 1966 and fellowship in neuropathology in 1967 at Case Western Reserve University in Cleveland, Ohio, and received his PhD in anatomy from the University of Rochester in 1971. Dr. Martin began his career in academic medicine at McGill University in Montreal, where he eventually became Chair of the Department of Neurology and Neurosurgery in 1977. In 1978, he joined the faculty of Harvard Medical School in Boston as the Bullard Professor of Neurology and Chief of the Neurology service at the Massachusetts General Hospital. In 1984, he was appointed the Julieanne Dorn Professor of Neurology at Harvard. Dr. Martin's research focused on hypothalamic regulation of pituitary hormone secretions and on application of neurochemical and molecular genetics to better understand the causes of neurological and neurodegenerative disease.

## Dr. Michael Brownstein

Dr. Brownstein has over thirty years of research experience in the fields of genetics, endocrinology and pharmacology. He earned his bachelor's degree from Columbia University; completed his graduate training at University of Chicago, where he earned an M.D. and Ph.D. in pharmacology; and received his clinical training at the Boston Children's Hospital. He then moved to the National Institutes of Health to work with Julius Axelrod, recipient of a Nobel Prize in 1970 for his studies in the fi eld of neuropharmacology, and remained at NIH after completing his fellowship. Dr. Brownstein served at the NIH as Chief of the Laboratory of Genetics of the National Institute of Mental Health and the National Human Genome Research Institute; and for two years as the Scientific Director of the NIMH Intramural Research Program.

THE UNIVERSITY OF CHICAGO

UNIVERSITY OF CAMBRIDGE

## Dr. John Trowsdale

Dr. Trowsdale is an Emeritus Professor, specialist in Immunogenetics, in the Department of Pathology, University of Cambridge UK. In the early 1980's he was one of the first to clone HLA genes and to complete sequencing of the entire HLA region. In collaboration with Stephan Beck at the Sanger Centre he provided sequenced common HLA haplotypes, which were used as 'gold-standard' references. John's interest in GenDx is in further development of rapid genetic analysis of highly variable genes such as HLA and KIR in human disease, such as infection, autoimmunity, cancer and pregnancy disorders. The link with GenDx is of mutual bene fi t in driving forward the use of next generation sequencing techniques to achieve rapid and accurate immunogenetic analysis. John visits GenDx to discuss how development of novel techniques at GenDx benefits the research and health care communities.

## Sean Power, CPA - Capital Markets Advisor

Highly accomplished, results driven professional with 16+ years of experience in financial leadership, M&A and capital raises, with transactions and financings exceeding $700 million . Mr. Power was part of the executive team that founded TG Therapeutics, Inc. (NASDAQ: TGTX) in 2011. a biopharmaceutical company focused on the development and commercialization of treatment options for patients with B-cell diseases. Under his leadership as CFO, TGTX has grown to a market capitalization of over $3 billion, with 40 clinical trials underway, and 5 medicines under development.

Sean has over 10 years of experience in the biotechnology industry where he has been responsible for a NASDAQ listing, managing a hedge fund, growing a team of over 170 staff and creating value for shareholders with a focus on growth and liquidity.

TG Therapeutics

# MYND In The News








# Capitalization Table

| | |
|---|---|
| Founders Management and IP Consideration | 37,183,382 |
| $0.30 Financing | 3,333,333 |
| Total Share Issued & Outstanding | 45,933,342 |
| Fully Diluted Shares Outstanding | 49,363,342 |

# Appendix A

# IP Portfolio - Biomarker & Test Kits

This patent is the basis for the development of our Diagnostic business

**Biomarker** - Human Mycogene biomarker used in diagnosing and monitoring depression and other autoimmune diseases. The present invention, is based on the discovery that ABCF1 is a strong negative regulator of pro-inflammatory responses and changes in ABCF1 activity/ expression is associated with a number of inflammatory and/ or autoimmune diseases. Accordingly, ABCF1 may be used as a biomarker alone or in combination with other for diagnosing and monitoring inflammatory responses and/or disease progression/treatment inflammatory and/or autoimmune diseases.

# IP Portfolio - MDD Patent

This patent is the basis for the development of MYND-604

**MDD** - Modulation of Human Mycogene in the treatment of depression In certain embodiments, the present invention provides treatments for inflammatory autoimmune disease and neuropsychiatric disorders associated with neuroinflammation by immune modulation. Non-limiting examples of methods to enhance expression and/or activity of ABCF1, include administration of the ABCF1, or active fragments thereof, administration of a nucleic acid or vector which encodes the ABCF1 or administration of one or more molecules which enhance expression of ABCF1. This patent provides a method of inhibiting neuroinflammation to treat neuropsychiatric disorders, including but not limited to MDD, schizophrenia, anxiety, bipolar disorder, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), and autism spectrum disorder.

Exemplary compounds also included in this patent are not limited to Psilocybin ( [3-(2-Dimethylaminoethyl)- 1H-indol-4-yl] dihydrogen phosphate), Psilocybin (zwitterion form), Psilocin (4-hydroxy-N,Ndimethyltryptamine), but also Serotonin (5-Hydroxytryptamine), DMT (N,N-Dimethyltryptamine), Lysergic acid diethylamide (LSD, (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9- hexahydroindolo[4,3-fg]quinoline-9-carboxamide, psilocin iminoquinone, psilocin o-quinone

# IP Portfolio - Sepsis Patent

This patent is the basis for the development of MYND-778

**Sepsis** - Modulation of Human Mycogene in the treatment of sepsis, autoimmune diseases, cancer and/or infections In accordance with an aspect of the invention, there is provided a method of inhibiting an inflammatory response and/or an immune response in a patient in need thereof, the method comprising administering an agonist of Mycogene thereby preventing and/or treating diseases involving inflammation

The patent relates to the regulation of inflammation and immune responses by modulating the human mycogene and turning a pro-inflammatory state in to an anti-inflammatory state.

There is provided in the patent, a method for inhibiting an inflammatory response and/or an immune response by administration of an agonist to the Human Mycogene.

# IP Portfolio - Alzheimers

This patent is the basis for the development of CNS Vaccines

**Alzheimers** - Accordingly, inhibiting angiogenesis and/or neuro-inflammation may prevent and/or treat Alzheimer's Disease and other dementias. A number of psychedelics have been shown to have anti-inflammatory and/or anti-angiogenic properties. A number of psychedelics have also been shown to promote neuroplasticity (i.e., the ability of the brain to form and
reorganize synaptic connections). Promoting the ability of the brain to form and reorganize synaptic connections may delay the progression of dementia.

# Appendix B

# Key Management Bio's

## Dr. Cheryl Pfeifer, PHD
### Senior Research Scientist

Dr. Cheryl Pfeifer has been involved with immunological research for over 30 years. She holds a Bachelor of Science and a Masters in Veterinary Microbiology from the University of Saskatchewan, and a PhD (1999) in Microbiology and Immunology from the University of British Columbia. After completing a postdoctorate with Dr. Wilf Jefferies, she has continued to work closely with him for the past 20 years on projects ranging from Alzheimer's disease and the blood-brain barrier, to the immune escape of cancer, to the regulation of the immune system using vaccines and small molecules. Dr. Pfeifer is a multi-disciplinary scientist with proven experience mentoring students and postdoctoral fellows, and managing multi-faceted teams to achieve the research goals. She has extensive experience as a grant facilitator and as a collaborative scientific researcher, with 15+ peer-reviewed publications and 4 patents.

## Dr. Chaahat SB Singh, PHD
### Senior Research Scientist

Dr. Cheryl Pfeifer has been involved with immunological research for over 30 years. She holds a Bachelor of Science and a Masters in Veterinary Microbiology from the University of Saskatchewan, and a PhD (1999) in Microbiology and Immunology from the University of British Columbia. After completing a postdoctorate with Dr. Wilf Jefferies, she has continued to work closely with him for the past 20 years on projects ranging from Alzheimer's disease and the blood-brain barrier, to the immune escape of cancer, to the regulation of the immune system using vaccines and small molecules. Dr. Pfeifer is a multi-disciplinary scientist with proven experience mentoring students and postdoctoral fellows, and managing multi-faceted teams to achieve the research goals. She has extensive experience as a grant facilitator and as a collaborative scientific researcher, with 15+ peer-reviewed publications and 4 patents.

## Dr. Iryna Saranchova, PHD
### Chief Clinical Officer

Dr. Iryna Saranchova has over two decades of experience in immunology and clinical research. She earned her MD from the Lviv Medical University (Ukraine) and her PHD in Immunology from the University of British Columbia (Canada). Dr. Saranchova also holds Certificates from The Johns Hopkins University (USA) and Vanderbilt University (USA) in Design and Interpretation of Clinical Trials, as well as in Data Management for Clinical Research. With several clinical trials designed and executed, she will be an integral member of the MYND management team moving forward.

## Jordan Cleland
### Chief Operating Officer

Jordan Cleland is the Chief Operating Officer of MYND Life Sciences. He previously operated Jordan Cleland Consulting, a communications, public relations, fundraising, leadership coaching and strategy practice. Cleland formerly served as Vice President, Advancement at Olds College in Alberta, Canada where he maximized reputation and relationships with media, alumni, donors, prospective students and governments. Jordan was presented the Gold Medal for Excellence in Leadership at the 2013 Colleges and Institutes Canada conference.Cleland earned a Master's in Leadership through Otago Polytechnic in New Zealand and a Bachelor of Arts in Political Science from Whitworth University in Washington.


MYND™